Eli Lilly has announced plans to invest $27 billion in four new U.S. manufacturing facilities, marking the largest pharmaceutical expansion investment in the country’s history. The Indianapolis-based company revealed the initiative during a press conference in Washington, D.C., under the banner
Eli Lilly has announced a new $5.3 billion investment in its manufacturing site in Lebanon, Indiana, US. This investment increases the firm’s total investment in the site from $3.7 billion to $9 billion. The expansion will increase the manufacturing capacity
Briefing In a significant development within the field of diabetes research, Eli Lilly, a leader in pharmaceutical innovation, has announced its acquisition of Sigilon Therapeutics, in the pursuit of a functional cure for Type 1 diabetes (T1D). The acquisition, valued
Eli Lilly has made a significant move in its quest to revolutionize autoimmune disease treatment. The company announced its acquisition of Dice Therapeutics, a leading innovator in the development of therapies targeting autoimmune disorders $2.4 Billion USD. Briefing Eli Lilly’s
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
